Home/Pipeline/oNKord® (Inaleucel)

oNKord® (Inaleucel)

Acute Myeloid Leukemia (AML)

Phase 1/2aActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2a

Status

Active

Company

Glycostem

About Glycostem

Glycostem Therapeutics is a pioneering developer of allogeneic, off-the-shelf NK cell immunotherapies derived from umbilical cord blood stem cells. Its core technology platform enables the production of highly pure, safe, and cost-effective NK cell products, with a lead candidate, oNKord®, in a pivotal Phase I/IIa trial for AML. The company has established a strategic partnership with medac GmbH for commercialization and is expanding its pipeline to include next-generation CAR-NK and other engineered NK cell therapies targeting both hematological and solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active